FATAL PNEUMONITIS ASSOCIATED WITH INTENSITY-MODULATED RADIATION THERAPY FOR MESOTHELIOMA

Size: px
Start display at page:

Download "FATAL PNEUMONITIS ASSOCIATED WITH INTENSITY-MODULATED RADIATION THERAPY FOR MESOTHELIOMA"

Transcription

1 RAPID COMMUNICATION FATAL PNEUMONITIS ASSOCIATED WITH INTENSITY-MODULATED RADIATION THERAPY FOR MESOTHELIOMA AARON M. ALLEN, M.D.,* MARIA CZERMINSKA, M.S.,* PASI A. JÄNNE, M.D., PH.D., DAVID J. SUGARBAKER, M.D., RAPHAEL BUENO, M.D., JAY R. HARRIS, M.D.,* LAURENCE COURT, PH.D.,* AND ELIZABETH H. BALDINI, M.D., M.P.H.* *Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA; Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital, Boston, MA; Division of Thoracic Surgery, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA Purpose: To describe the initial experience at Dana-Farber Cancer Institute/Brigham and Women s Hospital with intensity-modulated radiation therapy (IMRT) as adjuvant therapy after extrapleural pneumonectomy (EPP) and adjuvant chemotherapy. Methods and Materials: The medical records of patients treated with IMRT after EPP and adjuvant chemotherapy were retrospectively reviewed. IMRT was given to a dose of 54 Gy to the clinical target volume in 1.8 Gy daily fractions. Treatment was delivered with a dynamic multileaf collimator using a sliding window technique. Eleven of 13 patients received heated intraoperative cisplatin chemotherapy (225 mg/m 2 ). Two patients received neoadjuvant intravenous cisplatin/pemetrexed, and 10 patients received adjuvant cisplatin/ pemetrexed chemotherapy after EPP but before radiation therapy. All patients received at least 2 cycles of intravenous chemotherapy. The contralateral lung was limited to a V20 (volume of lung receiving 20 Gy or more) of 20% and a mean lung dose (MLD) of 15 Gy. All patients underwent fluorodeoxyglucose positron emission tomography (FDG-PET) for staging, and any FDG-avid areas in the hemithorax were given a simultaneous boost of radiotherapy to 60 Gy. Statistical comparisons were done using two-sided t test. Results: Thirteen patients were treated with IMRT from December 2004 to September Six patients developed fatal pneumonitis after treatment. The median time from completion of IMRT to the onset of radiation pneumonitis was 30 days (range 5 57 days). Thirty percent of patients (4 of 13) developed acute Grade 3 nausea and vomiting. One patient developed acute Grade 3 thrombocytopenia. The median V20, MLD, and V5 (volume of lung receiving 5 Gy or more) for the patients who developed pneumonitis was 17.6% (range, %), 15.2 Gy (range, Gy), and 98.6% (range, %), respectively, as compared with 10.9% (range, %) (p 0.08), 12.9 Gy (range, Gy) (p 0.07), and 90% (range, %) (p 0.20), respectively, for the patients who did not develop pneumonitis. Conclusions: Intensity-modulated RT treatment for mesothelioma after EPP and adjuvant chemotherapy resulted in a high rate of fatal pneumonitis when standard dose parameters were used. We therefore recommend caution in the utilization of this technique. Our data suggest that with IMRT, metrics such as V5 and MLD should be considered in addition to V20 to determine tolerance levels in future patients Elsevier Inc. Mesothelioma, Intensity-modulated radiation therapy, Pneumonitis, Mean lung dose. INTRODUCTION Pleural mesothelioma is a largely fatal disease with an aggressive clinical course and a high mortality rate using currently available therapy. Median survival is 12 months (1). Death is often caused by local progression ultimately resulting in respiratory failure. There is no clear standard of care for mesothelioma, and the relatively low incidence of the disease has made the conduct of randomized controlled studies with adequate numbers of patients difficult. A minority of patients with mesothelioma have disease Reprint requests to: Aaron Allen, M.D., Dana-Farber Cancer Institute, Department of Radiation Oncology, Dana L2, 44 Binney Street, Boston, MA Tel: (617) ; Fax: (617) ; limited to the chest and are therefore candidates for aggressive surgical resection. Extrapleural pneumonectomy (EPP) has been associated with better local control than pleurectomy/decortication (2, 3). However, even with EPP, 80% of patients experience local tumor progression (2). Because of this, aggressive combined approaches utilizing adjuvant chemotherapy and conventional radiation therapy (trimodality therapy) have been attempted. In our earlier experience with trimodality therapy including EPP, hemithoracic radiation, and chemotherapy, the 5-year survival rate was only 14% (4). Acknowledgments Special thanks to Drs. Harvey Mamon and Bruce Johnson for their critical reading of the manuscript. Received Mar 8, 2006, and in revised form Mar 15, Accepted for publication Mar 16, 2006.

2 Fatal pneumonitis associated with IMRT for mesothelioma A. M. ALLEN et al. 641 Therefore, new avenues for improvements in local and systemic therapies have been attempted. In 2003, preliminary results were published describing the utilization of intensity-modulated radiotherapy (IMRT) in the adjuvant setting after EPP. These preliminary results suggested that IMRT could be safely administered and could provide a local control rate of greater than 80% (5 7), far better than other series of adjuvant radiation therapy using conventional techniques (8, 9). Based on these promising results, this technique was initiated at the Dana-Farber Cancer Institute/Brigham and Women s Hospital. In this report we describe our initial experience, which demonstrated a high treatment-related mortality rate from pneumonitis. METHODS AND MATERIALS From December 2004 to August 2005, 13 patients were treated with IMRT after EPP and adjuvant chemotherapy at the Dana- Farber Cancer Institute/Brigham and Women s Hospital. All patients underwent preoperative mediastinoscopy, computed tomography (CT), magnetic resonance imaging, and positron emission tomography (PET) scans to determine resectability. Surgeons in the division of thoracic surgery at Brigham and Women s Hospital performed an EPP. Twelve of 13 patients received intraoperative intrapleural heated cisplatin (225 mg/m 2 ) chemotherapy at the time of surgery on a Brigham and Women s Hospital Phase II protocol. Dana-Farber Cancer Institute/Harvard Cancer Center Institutional Review Board approval was obtained to retrospectively review the records of these 13 patients. Systemic therapy Vogelzang et al. showed that patients with unresectable mesothelioma treated with cisplatin/pemetrexed chemotherapy enjoyed a 2-month prolongation in median survival compared with patients who were treated with cisplatin alone (1). Therefore, patients in this series were treated with 3 4 cycles of adjuvant cisplatin/pemetrexed chemotherapy after EPP. Chemotherapy was administered as published (1) with cisplatin given at 75 mg/m 2 and pemetrexed at 500 mg/m 2 every 21 days. Dose modifications were performed as previously published (1). Two patients received neoadjuvant chemotherapy one received 6 cycles of pemetrexed/cisplatin and the other received 2 cycles of pemetrexed/cisplatin. For the 10 patients who received adjuvant chemotherapy, the median time from completion of EPP to initiation of chemotherapy was 2.5 months (range 6 weeks to 3 months), and the median time from completion of chemotherapy to initiation of radiation therapy was 1 month (range 1 3 months). Twelve of 13 patients received intraoperative heated cisplatin chemotherapy (225 mg/m 2 ) on a Phase II institutional protocol. One patient developed renal insufficiency after treatment with intraoperative chemotherapy and was deemed unable to receive any intravenous chemotherapy. Patients treated in the adjuvant setting received at least 2 cycles of intravenous cisplatin/pemetrexed chemotherapy, 4 patients received 3 cycles of chemotherapy, and 1 patient received 4 cycles of chemotherapy. Restaging and radiotherapy planning At the time of the final cycle of chemotherapy, patients underwent a restaging PET/CT scan. Patients found to have distant disease in the abdomen or contralateral chest were deemed ineligible for radiation therapy. All patients deemed eligible for radiation therapy underwent CT simulation for radiation therapy planning. The patients were simulated with arms up and immobilized in a vac-loc bag with the use of a wing board (Med-Tec, Orange City, IA). A 1-cm bolus was placed over all thoracotomy scars for the planning scans. Patients were scanned at free breathing from the midneck to the pelvis to enable contouring and to assist with PET fusion. Contouring and target volume delineation The radiation oncologists (A.M.A., E.H.B.) drew the Clinical Target Volume 54 (CTV54) on each relevant slice from the lung apex to upper abdomen to include all areas of preoperative pleural surfaces. Volumes also included ipsilateral mediastinal lymph nodes and retrocrural space as defined by Ahamad et al. (7). When the CTV approximated critical structures such as spinal cord, heart, or liver, an alternative lower dose CTV (CTV 48) was defined to ensure appropriate sparing of critical structures. Thoracotomy scars were also included in the CTV54. Boost gross tumor volume (bgtv60) was defined based on areas of surgical concern such as positive margins or suspicion of residual disease and foci of PET-avidity on the restaging PET/CT done before radiation therapy. Normal tissue organs including liver, heart, esophagus, kidneys, contralateral lung, gastrointestinal tract, and spinal cord were also contoured on all relevant axial CT images. Dose prescription and optimization parameters The primary target volume CTV 54 was prescribed to 54 Gy. This was based on our previous institutional standard to give 54 Gy in the adjuvant setting for mesothelioma on the basis of published data for conventional radiation therapy (10). As described above, when normal tissue constraints were difficult to achieve (in the mediastinum or close to the spinal cord), a separate CTV structure was defined and prescribed to a dose of 48 Gy as we prioritized the normal tissue constraints ahead of CTV coverage in the optimization. Normal tissue tolerances We adhered to the normal tissue constraints from the published IMRT data (6, 7), and these are listed in Table 1. Two modifications to these were made. First, a constraint on the liver consisting of a mean liver dose of 31 Gy was added based on recent liver tolerance data (11). The contralateral lung was also limited to a mean lung dose (MLD) of less than 15 Gy as proposed by multiple Normal tissue Contralateral lung Table 1. Intensity-modulated radiotherapy optimization parameters Contralateral kidney V15 20% Liver Heart V45 30% V50 20% Spinal cord Dose volume constraints V20 20% and Mean lung dose 15 Gy V30 33% and Mean liver dose 31 Gy No portion may receive 60 Gy 90% must receive 45 Gy No portion may receive 50 Gy Abbreviation: V20 volume of lung receiving 20 Gy or more. Intensity-modulated radiation therapy optimization constraints for normal tissues.

3 642 Table 2. Patient characteristics (n 13) Age median (range) 66 (39 68) Gender BWH stage Laterality Histology Chemotherapy 11 Male 2 Female 2 Stage I 11 Stage III 7 Right 6 Left 8 Epithelial 5 Mixed 12 Intraoperative heated cisplatin 10 Adjuvant cisplatin/pemetrexed 2 neoadjuvant cisplatin/pemtrexed Abbreviation: BWH Brigham and Women s Hospital. Demographic and treatment details for 13 patients undergoing intensity-modulated radiation therapy. authors with respect to treatment of non small-cell lung cancer (NSCLC) (12, 13). After an initial death from pneumonitis, the remaining 2 patients in our series were planned with a more stringent lung criterion of MLD less than 9.5 Gy. Dose calculation and optimization were done using the ECLIPSE (Varian, Palo Alto, CA) treatment planning system, and tissue heterogeneity corrections (modified Batho) were employed. We planned and treated using sliding-window IMRT. Patientspecific quality assurance was carried out using a single ion chamber (Exradin A14) and film (EDR2, Kodak) placed in a solid water phantom. The departmental tolerance for the absolute dose agreement between ion chamber and calculation was 3%. Relative dose distributions were compared by overlaying the calculated and measured isodose curves using RIT4 software (RIT, Colorado Springs, CO). Departmental policy for cases where the absolute dose agreement was greater than 3%, but less than 5% was to critically examine the relative dose distributions, and then adjust the monitor units by % if appropriate. Dosimetric and spatial accuracy of our IMRT planning and delivery has been independently verified using the anthropomorphic head phantom from the Radiologic Physics Center (Houston, TX). All patients had dose volume histograms (DVHs) calculated for all target and normal tissue organs. Toxicities were defined by National Cancer Institute Common Toxicity Criteria v3.0 (14). Statistical comparisons were done using two-sided t test. RESULTS Thirteen patients with resected mesothelioma were treated with IMRT after EPP and adjuvant chemotherapy from December 2004 to September The median age of the patients was 66 years (range, years). There were 11 men and 2 women. The complete patient characteristics are listed in Table 2. Acute toxicity Thirty percent (4 of 13) of patients experienced National Cancer Institute Grade 3 nausea and vomiting and 23% (3 of 13) developed Grade 2 nausea and vomiting during radiation therapy treatment. One patient developed acute Grade 3 thrombocytopenia during radiation therapy. No other Grade 3 or greater acute toxicity was seen; and specifically, there were no complaints of dyspnea during treatment. Posttreatment toxicity After completion of therapy, 6 of 13 patients (46%) developed Grade 5 pneumonitis. All 6 patients required ventilatory support and subsequently died as a result of this toxicity. The median time to onset of this toxicity was 30 days (range 5 57 days) from the completion of IMRT. In all patients, the pneumonitis was accompanied by a radiographic appearance of diffuse interstitial infiltrate in the entire contralateral lung. Septic superinfection was present in 5 of the 6 patients. Three patients had late Grade 3 thrombocytopenia. The cause of death in all patients was respiratory failure. An autopsy was obtained for 2 patients. In both cases, the lungs revealed diffuse alveolar damage and dense fibrosis. As shown in Table 3, we compared various DVH metrics for the patients who developed pneumonitis with those who did not. These comparisons were limited by small numbers and in the case of V5, by the fact that all patients except 2 had values above 81%. The complete clinical and dosimetric details for all patients are shown in Table 4. The median V20 for the patients who developed pneumonitis was 17.6% (range, %) as compared with 10.9% (range, %) for the patients who did not develop pneumonitis (p 0.08) The median MLD was 15.2 Gy (range, Gy) for patients with pneumonitis as compared with 12.9 Gy (range, Gy) for the patients who did not develop pneumonitis (p 0.07). The median V5 for the patients who developed pneumonitis was 98.6% (range, %) as compared with 90% (range %) (p 0.20) for the patients who did not develop pneumonitis. Of the remaining 7 patients, 4 have Table 3. Comparison of dosimetric values of patients with and without fatal pneumonitis All patients* Patients with pneumonitis* Patients without pneumonitis* Comparison of with and without pneumonitis V % (3 24%) 17.6% ( %) 10.9% ( %) p 0.08 MLD 13.8 (7.3 17) Gy 15.2 ( ) Gy 12.9 ( ) Gy p 0.07 V5 92.4% (66 100%) 98.6% (81 100%) 90% ( %) p 0.20 Abbreviations: MLD mean lung dose; V20 volume of lung receiving 20 Gy or more; V5 volume of lung receiving 5 Gy or more. Comparison of the primary dose volume histogram metrics in patients who developed and did not develop pneumonitis. p values were calculated with Student t test. * Values are expressed as median (range).

4 Fatal pneumonitis associated with IMRT for mesothelioma A. M. ALLEN et al. 643 Table 4. Dose volume parameters and pneumonitis for 13 patients treated with intensity-modulated radiation therapy for mesothelioma Patient Goals % Side Right Left Left Right Left Right Left Left Left Right Right Pneumonitis N N Y Y N N N Y Y Y Y CTV Vol (cc s) Boost vol (cc) Contralateral lung V Mean dose (Gy) V Liver V Mean dose (Gy) Esophagus V Heart V V Contralateral kidney V Technique No. of beam directions No. of beams Patient Goals % Side Right Right Pneumonitis N N CTV Vol (cc s) Boost vol (cc) 8.1 Contralateral Lung V Mean dose (Gy) < V Liver V Mean dose (Gy) Esophagus V Heart V V Contralateral kidney V Technique No. of beam directions 9 9 No. of beams Abbreviations: CTV clinical target volume; V20 volume of lung receiving 20 Gy or more; N no; Y yes. Full dose volume details on all 13 patients. Goals were as outlines. Numbers in bold reflect numbers in excess of goals. died of progressive mesothelioma with a median survival of 11 months from diagnosis (range, months). Three patients remain alive without evidence of disease with a median follow-up of 16 months (range, 15 to 17 months). The 2 patients who were treated and had a MLD 9.5 are alive and without recurrence or toxicity 7 months after treatment. DISCUSSION This small series demonstrates an unacceptably high rate of fatal pneumonitis after EPP with intraoperative cisplatin, adjuvant cisplatin/pemetrexed, and IMRT to a dose of 54 Gy delivered to the hemithorax. We have sought to determine why this regimen was so

5 644 much more toxic than expected. There are several possible explanations, and the true answer may lie in one or more of the following possibilities. The first possible explanation is that the addition of intrapleural or systemic chemotherapy before IMRT may have predisposed the patients in this series to develop combined modality pneumonitis. There is no published literature regarding the combination of intrapleural chemotherapy and radiation therapy. However, a possible explanation is that intrapleural chemotherapy increases the levels of circulating proinflammatory cytokines, which predisposed these patients to develop pneumonitis. In the literature describing intrapleural cisplatin chemotherapy, there are no reported increases in lung toxicity (15 17). The second possible explanation is an interaction between systemic chemotherapy and radiation therapy such as has been seen for gemcitabine and radiation therapy for the treatment of NSCLC (18 20). Pemetrexed and cisplatin are known to be radiosensitizing agents (21); however, a recent experience in NSCLC of concurrent radiation therapy and pemetrexed-based chemotherapy reported a low incidence of radiation pneumonitis (22). Perhaps the most likely explanation for the increased pulmonary toxicity is the dose volume effects of the IMRT on the contralateral lung after pneumonectomy. It is unclear, however, which of the various lung DVH metrics best predicts for pneumonitis after pneumonectomy. Limited comparable data from treatment of NSCLC are available because few patients with NSCLC are irradiated after a total pneumonectomy. However, three separate analyses of single lung toxicity modeling all have demonstrated a 10% incidence of pneumonitis for patients treated with MLD 15 Gy (12, 23, 24). In another study, no increased incidence of pneumonitis was seen in patients who underwent pneumonectomy followed by postoperative radiation therapy compared with patients who received radiation therapy without surgery (25). These data suggest that surgical resection may not significantly influence the tolerance of the remaining lung to radiation therapy when conventional techniques are used. However, the comparison is limited by the volume of radiotherapy in NSCLC and the differences between EPP and pneumonectomy. This would seem to suggest that the phenomenon, which occurs with IMRT, is fundamentally different than what has been studied previously. To assess the importance of the various DVH metrics (V20, MLD, and V5), we compared these metrics for the patients who developed pneumonitis with those who did not (Table 3). These comparisons were limited by small numbers and, in the case of V5, by the fact that all but 2 patients had values above 81%. We found that although all of the values on average were higher for patients with pneumonitis than those without pneumonitis, none of the differences were statistically significant. All but 3 patients in our series had a V20 of less than 20%, which should have been safe (the other 3 had V20 values of 21%, 22%, and 25%); however, an examination of the entire DVH curve shows that in our patients, because of IMRT delivery, almost the entire contralateral lung received a very low dose of irradiation. This is a phenomenon not usually seen with conventional radiation techniques. To assess the importance of this extent of low-dose lung irradiation, it is perhaps reasonable to compare this experience to experience with total body irradiation in which large portions of the lungs also receive low-dose irradiation. In a recent review of patients treated with total body irradiation, a statistically significant higher rate of radiation pneumonitis was seen for patients receiving an MLD greater than 9.5 Gy compared with those receiving 9.5 Gy (14% vs. 4%) (26). Even though this level of MLD is far lower than typically thought to be significant, in a setting of large volume irradiation of lung, an MLD of 9 may be more appropriate as tolerance than an MLD of 15. A similar criterion has been proposed by Ahamad et al. (5). Similarly, perhaps V20 is not the correct metric to use when considering techniques that deliver low-dose irradiation to large volumes of remaining lung tissue. In support of that theory, a large multi-institutional retrospective series of lung toxicity data found V13 to be a better predictor of pneumonitis than V20 or even MLD (27). More recently, a secondary analysis of a dose escalation study in patients with NSCLC showed that V5 was an even better predictor of pneumonitis than V20 or MLD (28). These data suggest that perhaps it is not only the amount of lung treated that is the critical metric, but also the amount of lung spared completely from irradiation that determines the risk of toxicity. The latter may be particularly important when using IMRT in treating mesothelioma. The early experience in the treatment of esophageal cancer with IMRT and three-dimensional conformal radiation therapy supports this possibility. A recent series showed a 16% incidence of postoperative pulmonary complications in patients treated to Gy, and the volume of lung spared at least 5 Gy was the most significant dose volume metric predictive of postoperative pulmonary complications (29). Another study of IMRT for NSCLC also produced a fatal pneumonitis that was not expected (30). When we retrospectively examined the parameter V5 for our patients treated with IMRT, we found that the majority of patients in our series had a V5 greater than 90%. These high V5 values may, in fact, have been a key contributor to the observed pulmonary toxicity either instead of or along with the MLD values greater than 9.5 Gy. In addition, our prescription dose of 54 Gy was higher than proposed by other investigators. However, we feel the V5, MLD, and V20 metrics are more relevant than the absolute total dose in predicting pneumonitis, although all of these metrics are interrelated. In conclusion, using the dosimetric parameters in our study, IMRT treatment for mesothelioma after EPP and adjuvant chemotherapy has produced a high rate of fatal pneumonitis. We therefore recommend caution in the utilization of this technique until there is a clearer understanding of the dose volume effects created by IMRT for this patient population. Although not established, our data suggest that, especially with IMRT, metrics such as V5 and MLD should be used in addition to V20 to determine tolerance levels in future patients treated with IMRT for mesothelioma. In particular, our data

6 suggest the need to consider whether low doses of radiation therapy given to the remaining lung are dangerous when using standard tolerance limits for MLD and V20. This experience should also serve to caution investigators who seek to use IMRT in yet unproven treatment settings (such as the treatment of NSCLC) as unexpected toxicities may arise. Nevertheless, the sparing of normal tissues, such as the heart and liver, and the increased coverage of the target volume that IMRT allows make this technique very appealing for the adjuvant treatment of mesothelioma after EPP. At our institution, we plan to conduct a Phase I trial of IMRT with revised, more stringent lung dose constraints.

FATAL PNEUMONITIS ASSOCIATED WITH INTENSITY-MODULATED RADIATION THERAPY FOR MESOTHELIOMA

FATAL PNEUMONITIS ASSOCIATED WITH INTENSITY-MODULATED RADIATION THERAPY FOR MESOTHELIOMA doi:10.1016/j.ijrobp.2006.03.012 Int. J. Radiation Oncology Biol. Phys., Vol. 65, No. 3, pp. 640 645, 2006 Copyright 2006 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/06/$ see front

More information

Calculation of Contra-lateral Lung Doses in Thoracic IMRT: An Experimental Evaluation

Calculation of Contra-lateral Lung Doses in Thoracic IMRT: An Experimental Evaluation Calculation of Contra-lateral Lung Doses in Thoracic IMRT: An Experimental Evaluation Deborah Schofield, Laurence Court, Aaron Allen, Fred Hacker, Maria Czerminska Department of Radiation Oncology Dana

More information

Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma

Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl, Andrew Hope, Thomas K Waddell, Shaf Keshavjee,

More information

Mesothelioma. Malignant Pleural Mesothelioma

Mesothelioma. Malignant Pleural Mesothelioma Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency

More information

Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background

Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the

More information

Table of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms

Table of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation

More information

Clinical Indications and Results Following Chest Wall Resection

Clinical Indications and Results Following Chest Wall Resection Clinical Indications and Results Following Chest Wall Resection for Recurrent Malignant Pleural Mesothelioma Ali SO, Burt BM, Groth SS, DaSilva MC, Yeap BY, Richards WG, Baldini EH and Sugarbaker DJ. Division

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

Brigham and Women s Hospital, Boston, MA, USA; 2 Verastem, Inc., Boston, MA, USA

Brigham and Women s Hospital, Boston, MA, USA; 2 Verastem, Inc., Boston, MA, USA Determination of Biomarker Response in a Phase II Window of Opportunity Study of Defactinib (VS 6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Resectable Malignant Pleural Mesothelioma

More information

Intensity-modulated radiotherapy and volumetric-modulated arc therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy

Intensity-modulated radiotherapy and volumetric-modulated arc therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 14, NUMBER 4, 2013 Intensity-modulated radiotherapy and volumetric-modulated arc therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy

More information

Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012

Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012 Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro Joon H. Lee 9/17/2012 Malignant Pleural Mesothelioma (Epidemiology) Incidence: 7/mil (Japan) to 40/mil (Australia) Attributed secondary to asbestos

More information

Department of Radiation Oncology H. Lee Moffitt Cancer Center Khosrow Javedan M.S, Craig Stevens MD, Ph.D., Ken Forster Ph.D.

Department of Radiation Oncology H. Lee Moffitt Cancer Center Khosrow Javedan M.S, Craig Stevens MD, Ph.D., Ken Forster Ph.D. Efficacy of IMRT with dot decimal compensators for radiotherapy of malignant pleural mesothelioma post extrapleural pneumonectomy Department of Radiation Oncology H. Lee Moffitt Cancer Center Khosrow Javedan

More information

intensity_modulated_radiation_therapy_imrt_of_abdomen_and_pelvis 11/2009 5/2016 5/2017 5/2016

intensity_modulated_radiation_therapy_imrt_of_abdomen_and_pelvis 11/2009 5/2016 5/2017 5/2016 Corporate Medical Policy Intensity Modulated Radiation Therapy (IMRT) of Abdomen File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_abdomen_and_pelvis

More information

Screening, early referral and treatment for asbestos related cancer

Screening, early referral and treatment for asbestos related cancer Screening, early referral and treatment for asbestos related cancer Marc de Perrot, MD, MSc, FRCSC Toronto Mesothelioma Research Program University of Toronto Asbestos related diseases Mesothelioma Lung

More information

Radiation Therapy in the Treatment of

Radiation Therapy in the Treatment of Lung Cancer Radiation Therapy in the Treatment of Lung Cancer JMAJ 46(12): 537 541, 2003 Kazushige HAYAKAWA Professor and Chairman, Department of Radiology, Kitasato University School of Medicine Abstract:

More information

Malignant Mesothelioma State of the Art

Malignant Mesothelioma State of the Art Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIG

More information

Small Cell Lung Cancer

Small Cell Lung Cancer Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually

More information

Corporate Medical Policy Intensity-Modulated Radiation Therapy (IMRT) of the Prostate

Corporate Medical Policy Intensity-Modulated Radiation Therapy (IMRT) of the Prostate Corporate Medical Policy Intensity-Modulated Radiation Therapy (IMRT) of the Prostate File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_the_prostate

More information

Malignant Mesothelioma Current Approaches to a Difficult Problem. Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center

Malignant Mesothelioma Current Approaches to a Difficult Problem. Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center Malignant Mesothelioma Current Approaches to a Difficult Problem Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center Malignant Pleural Mesothelioma Clinical Presentation Insidious

More information

Radiotherapy in locally advanced & metastatic NSC lung cancer

Radiotherapy in locally advanced & metastatic NSC lung cancer Radiotherapy in locally advanced & metastatic NSC lung cancer Dr Raj Hegde. MD. FRANZCR Consultant Radiation Oncologist. William Buckland Radiotherapy Centre. Latrobe Regional Hospital. Locally advanced

More information

Post-operative intrapleural chemotherapy for mesothelioma

Post-operative intrapleural chemotherapy for mesothelioma Post-operative intrapleural chemotherapy for mesothelioma Robert Kratzke, MD John Skoglund Chair for Lung Cancer Research Section of Heme-Onc-Transplant University of Minnesota Medical School Efficacy

More information

Radiation therapy involves using many terms you may have never heard before. Below is a list of words you could hear during your treatment.

Radiation therapy involves using many terms you may have never heard before. Below is a list of words you could hear during your treatment. Dictionary Radiation therapy involves using many terms you may have never heard before. Below is a list of words you could hear during your treatment. Applicator A device used to hold a radioactive source

More information

Malignant Pleural Mesothelioma in Singapore

Malignant Pleural Mesothelioma in Singapore RESEARCH COMMUNICATION C SP Yip 1, HN Koong 2, CM Loo 3, KW Fong 1* Abstract Aim: To examine the clinical characteristics and outcomes of malignant pleural mesothelioma (MPM) in Singapore. Methods and

More information

The Need for Accurate Lung Cancer Staging

The Need for Accurate Lung Cancer Staging The Need for Accurate Lung Cancer Staging Peter Baik, DO Thoracic Surgery Cancer Treatment Centers of America Oklahoma Osteopathic Association 115th Annual Convention Financial Disclosures: None 2 Objectives

More information

Treatment of Mesothelioma with Radiotherapy

Treatment of Mesothelioma with Radiotherapy 41 Treatment of Mesothelioma with Radiotherapy Ryan P. Smith and Stephen M. Hahn General Principles of Radiation Therapy Radiation therapy is a therapeutic modality that uses ionizing radiation to treat

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Intensity Modulated Radiation Therapy (IMRT) of Head and Neck File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_head_and_neck

More information

Malignant pleural mesothelioma P/D vs. EPP

Malignant pleural mesothelioma P/D vs. EPP 3 rd International Thoracic Oncology Congress Dresden, September 13 15, 2012 Malignant pleural mesothelioma P/D vs. EPP Walter Weder, MD Professor of Surgery Dokumentenname Datum Seite 1 Extrapleural Pneumonectomy

More information

A Practical Guide to Advances in Staging and Treatment of NSCLC

A Practical Guide to Advances in Staging and Treatment of NSCLC A Practical Guide to Advances in Staging and Treatment of NSCLC Robert J. Korst, M.D. Director, Thoracic Surgery Medical Director, The Blumenthal Cancer Center The Valley Hospital Objectives Revised staging

More information

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES LUNG SITE MESOTHELIOMA Lung Site Group Mesothelioma Date Guideline Created: April 2013 Authors: Dr. Meredith Giuliani, Dr. Andrea Bezjak 1.

More information

Columbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org

Columbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org Columbia University Mesothelioma Center www.mesocenter.org Multimodal clinical trials, treatment (surgery, radiation, chemotherapy) Peritoneal mesothelioma program Immunotherapy translational, experimental

More information

Lung Cancer Treatment Guidelines

Lung Cancer Treatment Guidelines Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,

More information

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3

More information

بسم هللا الرحمن الرحيم

بسم هللا الرحمن الرحيم بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma

More information

SAKK Lung Cancer Group. Current activities and future projects

SAKK Lung Cancer Group. Current activities and future projects SAKK Lung Cancer Group Current activities and future projects SAKK Lung Cancer Group Open group of physicians interested in lung cancer Mostly Medical Oncologists, but also Thoracic Surgeons Radiation

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Intensity Modulated Radiation Therapy for Tumors of the Central File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_for_tumors

More information

Brain Tumor Treatment

Brain Tumor Treatment Scan for mobile link. Brain Tumor Treatment Brain Tumors Overview A brain tumor is a group of abnormal cells that grows in or around the brain. Tumors can directly destroy healthy brain cells. They can

More information

PROTON THERAPY FOR MALIGNANT PLEURAL MESOTHELIOMA AFTER EXTRAPLEURAL PLEUROPNEUMONECTOMY

PROTON THERAPY FOR MALIGNANT PLEURAL MESOTHELIOMA AFTER EXTRAPLEURAL PLEUROPNEUMONECTOMY doi:1.116/j.ijrobp.29.11.6 Int. J. Radiation Oncology Biol. Phys., Vol. 78, No. 2, pp. 628 634, 21 Copyright Ó 21 Elsevier Inc. Printed in the USA. All rights reserved 36-316/$ see front matter PHYSICS

More information

Lung cancer forms in tissues of the lung, usually in the cells lining air passages.

Lung cancer forms in tissues of the lung, usually in the cells lining air passages. Scan for mobile link. Lung Cancer Lung cancer usually forms in the tissue cells lining the air passages within the lungs. The two main types are small-cell lung cancer (usually found in cigarette smokers)

More information

Clinical case Pleural mesothelioma. Francesco Lucio

Clinical case Pleural mesothelioma. Francesco Lucio Clinical case Pleural mesothelioma Francesco Lucio Malignat Pleural Mesothelioma Mesothelioma is a rare malignant tumour originating from the cells lining the mesothelial surface of the coelomic cavities

More information

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,

More information

Clinical outcome of postoperative highly conformal versus 3D conformal radiotherapy in patients with malignant pleural mesothelioma

Clinical outcome of postoperative highly conformal versus 3D conformal radiotherapy in patients with malignant pleural mesothelioma Krayenbuehl et al. Radiation Oncology 2014, 9:32 RESEARCH Open Access Clinical outcome of postoperative highly conformal versus 3D conformal radiotherapy in patients with malignant pleural mesothelioma

More information

Lung Cancer Treatment

Lung Cancer Treatment Scan for mobile link. Lung Cancer Treatment Lung cancer overview More than one in four of all diagnosed cancers involve the lung, and lung cancer remains the most common cancer-related cause of death among

More information

Activity of pemetrexed in thoracic malignancies

Activity of pemetrexed in thoracic malignancies Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is

More information

Radiotherapy in Lung

Radiotherapy in Lung Radiotherapy in Lung CancerAnatomy Oblique fissure in both lungs. Horizontal fissure in Right lung. Trachea bifurcates at the level of T5. Lymph nodes are divided into stations. Intrapulmonary, bronchopulmonary

More information

oracic Oncology Advances

oracic Oncology Advances Winter 2011 oracic Oncology Advances Page 2 Page 4 Page 6 Page 7 Innovative Clinical Trials and Research Expand Targeted Medical Therapies and Personalized Approaches to Lung Cancer Care Medical oncologists

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

More information

Acknowledgement. Prerequisites: Basic Concepts of IMRT. Overview. Therapy Continuing Education Course Clinical Implementation of IMRT for Lung Cancers

Acknowledgement. Prerequisites: Basic Concepts of IMRT. Overview. Therapy Continuing Education Course Clinical Implementation of IMRT for Lung Cancers Therapy Continuing Education Course Clinical Implementation of IMRT for Lung Cancers H. Helen Liu, PhD Department of Radiation Physics, U.T. MD Anderson Cancer Center, Houston, TX AAPM, Seattle, 2005 Acknowledgement

More information

Treatment of mesothelioma in Bloemfontein, South Africa

Treatment of mesothelioma in Bloemfontein, South Africa European Journal of Cardio-thoracic Surgery 24 (2003) 434 440 www.elsevier.com/locate/ejcts Treatment of mesothelioma in Bloemfontein, South Africa W.J. de Vries*, M.A. Long Cardiothoracic Department,

More information

Malignant Mesothelioma

Malignant Mesothelioma Malignant Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)

More information

MesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology

MesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology MesoPDT Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI Image Assisted Laser Therapy for Oncology Unité Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI "Image

More information

Malignant Mesothelioma

Malignant Mesothelioma Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)

More information

Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist

Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the

More information

TITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software.

TITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software. SAMPLE CLINICAL RESEARCH APPLICATION ABSTRACT: TITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software. Hypothesis:

More information

Corporate Medical Policy Intensity Modulated Radiation Therapy (IMRT) of the Chest

Corporate Medical Policy Intensity Modulated Radiation Therapy (IMRT) of the Chest Corporate Medical Policy Intensity Modulated Radiation Therapy (IMRT) of the Chest File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_the_chest

More information

Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines

Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines April 2008 (presented at 6/12/08 cancer committee meeting) By Shelly Smits, RHIT, CCS, CTR Conclusions by Dr. Ian Thompson, MD Dr. James

More information

PET/CT in Lung Cancer

PET/CT in Lung Cancer PET/CT in Lung Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria GLOBOCAN 2012 #1 #3 FDG-PET/CT

More information

Esophageal Cancer Treatment

Esophageal Cancer Treatment Scan for mobile link. Esophageal Cancer Treatment What is Esophageal Cancer? Esophageal cancer occurs when cancer cells develop in the esophagus, a long, tube-like structure that connects the throat and

More information

Round Table with Drs. Anne Tsao and Alex Farivar, Case 2: Mesothelioma

Round Table with Drs. Anne Tsao and Alex Farivar, Case 2: Mesothelioma Round Table with Drs. Anne Tsao and Alex Farivar, Case 2: Mesothelioma I d like to welcome everyone, thanks for coming out to our lunch with experts. The faculty today are great people in the thoracic

More information

Clinical Education A comprehensive and specific training program. carry out effective treatments from day one

Clinical Education A comprehensive and specific training program. carry out effective treatments from day one Proton Therapy Clinical Education A comprehensive and specific training program carry out effective treatments from day one Forewarned is forearmed Although over 100,000 patients have been treated in proton

More information

Lung Cancer and Mesothelioma

Lung Cancer and Mesothelioma Lung Cancer and Mesothelioma Robert Kratzke, M.D. John C. Skoglund Professor of Lung Cancer Research Section of Heme/Onc/Transplant Department of Medicine University of Minnesota Medical School Malignant

More information

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology

Mesothelioma. 1. Introduction. 1.1 General Information and Aetiology Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are

More information

Particle Therapy for Lung Cancer. Bradford Hoppe MD, MPH Assistant Professor University of Florida bhoppe@floridaproton.org

Particle Therapy for Lung Cancer. Bradford Hoppe MD, MPH Assistant Professor University of Florida bhoppe@floridaproton.org Particle Therapy for Lung Cancer Bradford Hoppe MD, MPH Assistant Professor University of Florida bhoppe@floridaproton.org Content Rationale for Particle Therapy in Lung Cancer Proof of Principle Treatment

More information

Helical TomoTherapy for Lung Cancer Radiotherapy: Good Science Pays Clinical Dividends Peter Hoban, Ph.D., TomoTherapy Inc.

Helical TomoTherapy for Lung Cancer Radiotherapy: Good Science Pays Clinical Dividends Peter Hoban, Ph.D., TomoTherapy Inc. CLINICAL FEATURE Helical TomoTherapy for Lung Cancer Radiotherapy: Good Science Pays Clinical Dividends Peter Hoban, Ph.D., TomoTherapy Inc. The Challenge Lung cancer kills more people each year in the

More information

Treatment Volume and Technique

Treatment Volume and Technique RADIATION THERAPY The standard of care for early lesions is surgical resection; however, selected patients with small central lesions may be considered for definitive radiation, particularly when the lesions

More information

Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate e P rofessor Professor Radiation Oncology

Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate e P rofessor Professor Radiation Oncology Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate Professor Radiation Oncology Disclosure Information I have no financial relationships to disclose relevant to the conten of this presentation.

More information

Probe: Could you tell me about when?

Probe: Could you tell me about when? PERIODIC ASSESSMENT OF TREATMENT AND VITAL/DISEASE STATUS Periodic Assessment of Cancer Treatment and Disease Status (To be administered to patient at 3 months and reviewed at 6, 9 and 12 months) Instructions:

More information

National Clinical Trials Network Groups Update Fall 2014

National Clinical Trials Network Groups Update Fall 2014 National Clinical Trials Network Groups Update Fall 2014 Walter J Curran, Jr, MD An NRG Oncology Group Chair Executive Director Winship Cancer Institute of Emory University Atlanta, GA NCTN Groups Update

More information

Intensity-Modulated Radiation Therapy (IMRT)

Intensity-Modulated Radiation Therapy (IMRT) Scan for mobile link. Intensity-Modulated Radiation Therapy (IMRT) Intensity-modulated radiotherapy (IMRT) uses linear accelerators to safely and painlessly deliver precise radiation doses to a tumor while

More information

Malignant Mesothelioma: an Update

Malignant Mesothelioma: an Update Malignant Mesothelioma: an Update Nico van Zandwijk Asbestos Diseases Research Institute Bernie Banton Centre University of Sydney Australia Physicians Week RACP 19-5-2009 Health Risks of Asbestos Fibers

More information

Surgical therapy of. who should be operated

Surgical therapy of. who should be operated SAMO Interdisciplinary Workshop on Chest Tumors Lucerne, 13th and 14th January 2012 Surgical therapy of mesothelioma, who should be operated Walter Weder MD Professor of Surgery University Hospital Zurich

More information

Stage I, II Non Small Cell Lung Cancer

Stage I, II Non Small Cell Lung Cancer Stage I, II Non Small Cell Lung Cancer Best Results T1 (less 3 cm) N0 80% 5 year survival No Role Adjuvant Chemotherapy Radiation Therapy Reduces Local Recurrence No Improvement in Survival 1 Staging Mediastinal

More information

Management of mesothelioma

Management of mesothelioma Management of mesothelioma Jan.vanmeerbeeck@ugent.be Amsterdam, March 6, 2010 1 management Palliation Symptomatic care Pain Breathlessness Radiotherapy Chemotherapy Surgery Radical (intention to cure)

More information

Sternotomy and removal of the tumor

Sternotomy and removal of the tumor Sternotomy and removal of the tumor All thymomas originate from epithelial thymic cells 4% of them consist of a pure population of epithelial cells Most have mixed populations of lymphoid cells to a

More information

Avastin: Glossary of key terms

Avastin: Glossary of key terms Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.

More information

PATIENT INFORMATION ABOUT ADJUVANT THERAPY AFTER THE WHIPPLE OPERATION FOR ADENOCARCINOMA ( CANCER ) OF THE PANCREAS AND RELATED SITES.

PATIENT INFORMATION ABOUT ADJUVANT THERAPY AFTER THE WHIPPLE OPERATION FOR ADENOCARCINOMA ( CANCER ) OF THE PANCREAS AND RELATED SITES. PATIENT INFORMATION ABOUT ADJUVANT THERAPY AFTER THE WHIPPLE OPERATION FOR ADENOCARCINOMA ( CANCER ) OF THE PANCREAS AND RELATED SITES. Radiation Oncology Sidney Kimmel Cancer Center at Johns Hopkins Last

More information

Guidelines for the treatment of breast cancer with radiotherapy

Guidelines for the treatment of breast cancer with radiotherapy London Cancer Guidelines for the treatment of breast cancer with radiotherapy March 2013 Review March 2014 Version 1.0 Contents 1. Introduction... 3 2. Indications and dosing schedules... 3 2.1. Ductal

More information

Bristol Hospital Cancer Care Center 2015 Annual Report

Bristol Hospital Cancer Care Center 2015 Annual Report Bristol Hospital Cancer Care Center 2015 Annual Report 2015 Annual Report Cancer Care Center At every point along the path, our team is there, keeping the focus on the most important team member - the

More information

Alternatives to Surgical Resection for Early Stage Lung Cancer

Alternatives to Surgical Resection for Early Stage Lung Cancer Alternatives to Surgical Resection for Early Stage Lung Cancer Neil A. Christie MD University of Pittsburgh Medical Center Department of Thoracic Surgery Allied Health Personnel Symposium AATS 2014 Conflicts

More information

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited

More information

THE DOSIMETRIC EFFECTS OF

THE DOSIMETRIC EFFECTS OF THE DOSIMETRIC EFFECTS OF OPTIMIZATION TECHNIQUES IN IMRT/IGRT PLANNING 1 Multiple PTV Head and Neck Treatment Planning, Contouring, Data, Tips, Optimization Techniques, and algorithms AAMD 2013, San Antonio,

More information

Outcomes of Patients With Stage III Nonsmall Cell Lung Cancer Treated With Chemotherapy and Radiation With and Without Surgery

Outcomes of Patients With Stage III Nonsmall Cell Lung Cancer Treated With Chemotherapy and Radiation With and Without Surgery Outcomes of Patients With Stage III Nonsmall Cell Lung Cancer Treated With Chemotherapy and Radiation With and Without Surgery Hale B. Caglar, MD 1 ; Elizabeth H. Baldini, MD, MPH 1 ; Megan Othus, MS 2

More information

POLICY A. INDICATIONS

POLICY A. INDICATIONS Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below

More information

People Living with Cancer

People Living with Cancer Patient Guide ASCOInformation for People Living with Cancer ADVANCED LUNG CANCER TREATMENT Recommendations of the American Society of Clinical Oncology Welcome The American Society of Clinical Oncology

More information

Current Status and Perspectives of Radiation Therapy for Breast Cancer

Current Status and Perspectives of Radiation Therapy for Breast Cancer Breast Cancer Current Status and Perspectives of Radiation Therapy for Breast Cancer JMAJ 45(10): 434 439, 2002 Masahiro HIRAOKA, Masaki KOKUBO, Chikako YAMAMOTO and Michihide MITSUMORI Department of Therapeutic

More information

Non-Small Cell Lung Cancer Therapies

Non-Small Cell Lung Cancer Therapies Non-Small Cell Lung Cancer Therapies Guest Expert: Roy, MD, PhD Assistant Professor of Therapeutic Radiology Scott, MD Assistant Professor of Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome

More information

Radiation Protection in Radiotherapy

Radiation Protection in Radiotherapy Radiation Protection in Radiotherapy Albert Lisbona Medical Physics Department CLCC Nantes Atlantique 44805 Saint-Herblain France a-lisbona@nantes.fnclcc.fr Radiation therapy The lecture is oriented to

More information

Tricia Cox on 7/18/2012 at Oncology Center. Sarah Randolf. Female

Tricia Cox on 7/18/2012 at Oncology Center. Sarah Randolf. Female SAMPLE This Survivorship Care Plan will facilitate cancer care following active treatment. It may include important contact information, a treatment summary, recommendations for follow-up care testing,

More information

Management of spinal cord compression

Management of spinal cord compression Management of spinal cord compression (SUMMARY) Main points a) On diagnosis, all patients should receive dexamethasone 10mg IV one dose, then 4mg every 6h. then switched to oral dose and tapered as tolerated

More information

The Canadian National System for Incident Reporting in Radiation Treatment (NSIR-RT) Taxonomy March 2, 2015 V2

The Canadian National System for Incident Reporting in Radiation Treatment (NSIR-RT) Taxonomy March 2, 2015 V2 The Canadian National System for Incident Reporting in Radiation Treatment (NSIR-RT) Taxonomy March 2, 2015 V2 Taxonomy Data Category Number Description Data Fields and Menu Choices 1. Impact 1.1 Incident

More information

Neoadjuvant radiotherapy: Necessary for treatment of rectal cancer. Shannon Acker April 4, 2011

Neoadjuvant radiotherapy: Necessary for treatment of rectal cancer. Shannon Acker April 4, 2011 Neoadjuvant radiotherapy: Necessary for treatment of rectal cancer Shannon Acker April 4, 2011 Rectal Cancer 40,870 new cases in the US in 2009 49,920 deaths from colorectal cancer Second leading cause

More information

Treatment of Stage III Non-small Cell Lung Cancer

Treatment of Stage III Non-small Cell Lung Cancer CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES Treatment of Stage III Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of

More information

Definitive Treatment of Poor-Risk Patients with Stage I Lung Cancer. A Single Institution Experience

Definitive Treatment of Poor-Risk Patients with Stage I Lung Cancer. A Single Institution Experience ORIGINAL ARTICLE Definitive Treatment of Poor-Risk Patients with Stage I Lung Cancer A Single Institution Experience Michael Hsie, MD,* Stefania Morbidini-Gaffney, MD,* Leslie J. Kohman, MD, Elisabeth

More information

PRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology

PRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology PRODYNOV Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI Image Assisted Laser Therapy for Oncology Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI

More information

NOTTINGHAM UNIVERSITY NHS TRUST BREAST INSTITUTE GUIDELINE NEOADJUVANT CHEMOTHERAPY (NACT) FOR BREAST CANCER

NOTTINGHAM UNIVERSITY NHS TRUST BREAST INSTITUTE GUIDELINE NEOADJUVANT CHEMOTHERAPY (NACT) FOR BREAST CANCER NOTTINGHAM UNIVERSITY NHS TRUST BREAST INSTITUTE GUIDELINE NEOADJUVANT CHEMOTHERAPY (NACT) FOR BREAST CANCER Definitions: NACT is recommended initial treatment for inflammatory breast cancer and inoperable

More information

1) Thoracic Surgery, Kyoto University Hospital. 2) Radiation Oncology and Image-Applied Therapy, Kyoto University Hospital

1) Thoracic Surgery, Kyoto University Hospital. 2) Radiation Oncology and Image-Applied Therapy, Kyoto University Hospital Title Survival and relapse pattern after malignant pleural mesothelioma. Okubo, Kenichi; Sonobe, Makoto; Fuj Author(s) Tsuyoshi; Sakai, Hiroaki; Miyahara, Hiroshi; Shibuya, Keiko; Hiraoka, M Citation General

More information

Summary of treatment benefits

Summary of treatment benefits Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell

More information

REPORT ASCO 1998 LOS ANGELES : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group

REPORT ASCO 1998 LOS ANGELES : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group REPORT ASCO 1998 LOS ANGELES : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group Educational session Treatment of stage III non-small cell lung cancer (NSCLC) in

More information

The Clinical Case for Individualized Use of Proton Beam Therapy

The Clinical Case for Individualized Use of Proton Beam Therapy The Clinical Case for Individualized Use of Proton Beam Therapy According to physicians and researchers who use proton beam therapy, the technology is a long-needed, excellent alternative to use of conventional

More information

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent

More information

Downloaded from: http://researchonline.lshtm.ac.uk/278/

Downloaded from: http://researchonline.lshtm.ac.uk/278/ Treasure, T; Lang-Lazdunski, L; Waller, D; Bliss, JM; Tan, C; Entwisle, J; Snee, M; O Brien, M; Thomas, G; Senan, S; O Byrne, K; Kilburn, LS; Spicer, J; Landau, D; Edwards, J; Coombes, G; Darlison, L;

More information